Related Experiment Videos
Lymph node sampling and survival in endometrial cancer
E L Trimble1, C Kosary, R C Park
1National Cancer Institute, Bethesda, Maryland, 20892-7436, USA.
Gynecologic Oncology
|January 15, 1999
Summary
Pelvic lymph node sampling in early-stage endometrial cancer generally does not improve survival. However, it may benefit select patients with stage I, grade 3 disease, warranting careful patient selection.
Area of Science:
- Gynecologic Oncology
- Surgical Pathology
- Cancer Epidemiology
Background:
- Endometrial adenocarcinoma staging is crucial for treatment decisions.
- Pelvic lymph node sampling is a component of surgical staging.
Purpose of the Study:
- To evaluate the impact of pelvic lymph node sampling on survival in women with FIGO stage I and II endometrial adenocarcinoma.
Main Methods:
- Analysis of Surveillance, Epidemiology, and End Results (SEER) data from 9185 women with stage I and 881 women with stage II endometrial cancer.
- Life table analysis was employed to compare survival rates between women who underwent lymph node sampling and those who did not.
Main Results:
- Overall, pelvic lymph node sampling did not demonstrate a significant survival benefit for early-stage endometrial cancer.
- A significant survival advantage was observed for women with stage I, grade 3 endometrial cancer who underwent lymph node sampling (5-year relative survival 0.89 vs. 0.81).
- No significant survival benefit was noted for stage I, grade 1 or grade 2 disease.
Conclusions:
- The survival benefit in a subset of patients may be linked to identifying more advanced disease.
- Accurate tumor grading and staging are essential for selecting appropriate candidates for lymph node sampling.
- Collaboration between surgical pathology and gynecology is vital for optimal specimen evaluation and patient management.